EGFR and non-small cell lung carcinoma: This investigation was followed by further expansion of the database sample size, and afatinib may be the initial treatment of preference for NSCLC patients with major uncommon EGFR mutations according to the findings, which showed that it was responsive to these mutations (median TTF: 12.6 months; 95% CI: 11.5–15.9; ORR: 59.0%) [15].